References:
1. Jean, S.S., Lee, P.I., and Hsueh, P.R., Treatment options for
COVID-19: The reality and challenges. J Microbiol Immunol Infect, 2020.53 (3): p. 436-443.
2. Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S.,
Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., Kline, S., Lopez
de Castilla, D., Finberg, R.W., Dierberg, K., Tapson, V., Hsieh, L.,
Patterson, T.F., Paredes, R., Sweeney, D.A., Short, W.R., Touloumi, G.,
Lye, D.C., Ohmagari, N., Oh, M.D., Ruiz-Palacios, G.M., Benfield, T.,
Fatkenheuer, G., Kortepeter, M.G., Atmar, R.L., Creech, C.B., Lundgren,
J., Babiker, A.G., Pett, S., Neaton, J.D., Burgess, T.H., Bonnett, T.,
Green, M., Makowski, M., Osinusi, A., Nayak, S., Lane, H.C., and
Members, A.-S.G., Remdesivir for the Treatment of Covid-19 -
Preliminary Report. N Engl J Med, 2020.
3. Group, R.C., Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell,
J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi,
E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan,
C., Chappell, L.C., Faust, S.N., Jaki, T., Jeffery, K., Montgomery, A.,
Rowan, K., Juszczak, E., Baillie, J.K., Haynes, R., and Landray, M.J.,Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary
Report. N Engl J Med, 2020.
4. Li, G. and De Clercq, E., Therapeutic options for the 2019
novel coronavirus (2019-nCoV). Nat Rev Drug Discov, 2020.19 (3): p. 149-150.
5. Weiss, P. and Murdoch, D.R., Clinical course and mortality risk
of severe COVID-19. Lancet, 2020. 395 (10229): p. 1014-1015.
6. Tale, S., Ghosh, S., Meitei, S.P., Kolli, M., Garbhapu, A.K., and
Pudi, S., Post COVID -19 Pneumonia Pulmonary Fibrosis. QJM, 2020.
7. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L.,
Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W.,
Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J.,
Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., and Cao, B.,Clinical features of patients infected with 2019 novel coronavirus
in Wuhan, China. Lancet, 2020. 395 (10223): p. 497-506.
8. Report of the WHO-China Joint Mission on Coronavirus Disease
2019 (COVID-19) . 2020 [cited 2020 29 september]; Available from:
https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
9. Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S.,
Manson, J.J., and Hlh Across Speciality Collaboration, U.K.,COVID-19: consider cytokine storm syndromes and
immunosuppression. Lancet, 2020. 395 (10229): p. 1033-1034.
10. Piechotta, V., Chai, K.L., Valk, S.J., Doree, C., Monsef, I., Wood,
E.M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., Estcourt,
L.J., and Skoetz, N., Convalescent plasma or hyperimmune
immunoglobulin for people with COVID-19: a living systematic review.Cochrane Database Syst Rev, 2020. 7 : p. CD013600.
11. Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y.,
Xiao, W., Liu, S., Chen, E., Chen, W., Wang, X., Yang, J., Lin, J.,
Zhao, Q., Yan, Y., Xie, Z., Li, D., Yang, Y., Liu, L., Qu, J., Ning, G.,
Shi, G., and Xie, Q., Hydroxychloroquine in patients with mainly
mild to moderate coronavirus disease 2019: open label, randomised
controlled trial. BMJ, 2020. 369 : p. m1849.
12. Lamontagne, F., Agoritsas, T., Macdonald, H., Leo, Y.S., Diaz, J.,
Agarwal, A., Appiah, J.A., Arabi, Y., Blumberg, L., Calfee, C.S., Cao,
B., Cecconi, M., Cooke, G., Dunning, J., Geduld, H., Gee, P., Manai, H.,
Hui, D.S., Kanda, S., Kawano-Dourado, L., Kim, Y.J., Kissoon, N.,
Kwizera, A., Laake, J.H., Machado, F.R., Qadir, N., Sarin, R., Shen, Y.,
Zeng, L., Brignardello-Petersen, R., Lytvyn, L., Siemieniuk, R.,
Zeraatkar, D., Bartoszko, J., Ge, L., Maguire, B., Rochwerg, B., Guyatt,
G., and Vandvik, P.O., A living WHO guideline on drugs for
covid-19. BMJ, 2020. 370 : p. m3379.
13. Mo, X., Jian, W., Su, Z., Chen, M., Peng, H., Peng, P., Lei, C.,
Chen, R., Zhong, N., and Li, S., Abnormal pulmonary function in
COVID-19 patients at time of hospital discharge. Eur Respir J, 2020.55 (6).
14. Wilson, M.S. and Wynn, T.A., Pulmonary fibrosis: pathogenesis,
etiology and regulation. Mucosal Immunol, 2009. 2 (2): p.
103-21.
15. Kendall, R.T. and Feghali-Bostwick, C.A., Fibroblasts in
fibrosis: novel roles and mediators. Front Pharmacol, 2014. 5 :
p. 123.
16. Razzaque, M.S. and Taguchi, T., Pulmonary fibrosis: cellular
and molecular events. Pathol Int, 2003. 53 (3): p. 133-45.